A Closed Solution For T Cell Isolation And Activation With CTS Dynabeads Magnetic Beads And The CTS Rotea Counterflow Centrifugation System

Robust manufacturing processes that will enable standardization of CAR T cell production, reduce manufacturing failure rates, and ultimately reinforce high-quality production standards and positive clinical outcomes are critical. Open processing and manual handling can introduce contamination, inconsistency, and lot-to-lot variability that lead to failure. The infrastructure, materials, time, and skilled labor needed for successful autologous T cell production also make CAR T therapeutics extremely expensive. Moving to a closed, modular workflow that integrates the complex process of CAR T cell manufacturing and reduces the number of manual steps could improve consistency, purity, and the safety of these therapeutics while helping to reduce their cost.

As part of our initiative to provide workflows that support closed, modular, and automated cell therapy manufacturing, we outline the incorporation of magnetic bead separation technology into a cell processing platform designed specifically for cell therapy applications.